CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Live Science on MSNOpinion
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...
Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.
CRISPR Therapeutics › Investing in modestly sized growth stocks can lead to significant returns, but oftentimes it requires taking on a fair bit of risk and being willing to wait at least a few years ...
Jennifer Doudna is a Nobel laureate in chemistry and professor of biochemistry, biophysics and structural biology at the University of California, Berkeley. She has been a pioneer in CRISPR gene ...
A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback